| Ocular findings in COVID‐19 patients: a review of direct manifestations and indirect effects on the eye F Bertoli, D Veritti, C Danese, F Samassa, V Sarao, N Rassu, T Gambato, ... Journal of ophthalmology 2020 (1), 4827304, 2020 | 172 | 2020 |
| Pharmacotherapy for treatment of retinal vein occlusion V Sarao, F Bertoli, D Veritti, P Lanzetta Expert Opinion on Pharmacotherapy 15 (16), 2373-2384, 2014 | 21 | 2014 |
| Ocular findings in COVID-19 patients: a review of direct manifestations and indirect effects on the eye. J Ophthalmol 2020; 2020: 4827304 F Bertoli, D Veritti, C Danese, F Samassa, V Sarao, N Rassu | 13 | |
| A 5-year-old case of choroidal neovascularization in enhanced S-cone syndrome treated with ranibizumab F Bertoli, S Pignatto, F Rizzetto, P Lanzetta Case Reports in Ophthalmology 9 (3), 510-515, 2019 | 11 | 2019 |
| Electrophysiological and SD-OCT findings in patients receiving chloroquine therapy in relation to cumulative dosage and duration of treatment F Bertoli, M Šuštar, M Jarc Vidmar, D Perovšek, J Brecelj, Š Markelj, ... Documenta Ophthalmologica 141, 1-14, 2020 | 6 | 2020 |
| Effects of antithrombotic agents on ophthalmological outcomes, cardiovascular risk, and mortality in hypertensive patients with retinal vein occlusion: an exploratory … F Bertoli, B Bais, D De Silvestri, B Mariotti, D Veritti, A Cavarape, ... Medicina 57 (10), 1017, 2021 | 3 | 2021 |
| Ozurdex for macular edema due to retinal vein occlusion: what is the duration of action? D Veritti, S Macor, F Bertoli, A Renna, P Lanzetta Investigative Ophthalmology & Visual Science 56 (7), 3755-3755, 2015 | | 2015 |
| Pharmacotherapy for treatment of retinal vein occlusion Response V Sarao, F Bertoli, D Veritti, P Lanzetta EXPERT OPINION ON PHARMACOTHERAPY 16 (3), 448-448, 2015 | | 2015 |
